


# ClinicalTrials.gov

## *Registration and Results Reporting*



Laverne Estanol, M.S., CHRC, CIP  
*Assistant Director, Human Research Protections*

# NIH POLICY

## Scope and Applicability <sup>1</sup>

The **NIH Policy on the Dissemination of NIH-Funded Clinical Trial Information** covers all applications for funding (including grants, contracts, and other transactions) submitted **on or after January 18, 2017** that request support for the conduct of any clinical trial. <sup>2</sup> The policy **does not apply** to clinical trials in ongoing, non-competing awards, but will apply if the grantee submits a competing renewal application that includes a new clinical trial. <sup>2</sup> The policy **does not apply** to a clinical trial that *uses NIH-supported infrastructure but does not receive NIH funds to support its conduct.* <sup>3</sup>

Although the policy **does not apply** to NIH-funded clinical trials initiated before the effective date, *NIH encourages all ongoing NIH-funded clinical trials to follow this policy.* <sup>4</sup> Investigators conducting *NIH-funded applicable clinical trials that are subject to the statute\* and rule\*\** also need to be in compliance with those requirements. <sup>4, 5</sup>

The policy **does not apply** to:

- clinical trials in ongoing, non-competing awards
- a clinical trial that *uses NIH-supported infrastructure but does not receive NIH funds to support its conduct*
- NIH-funded clinical trials initiated before the effective date

The policy **applies**:

- to all applications for funding (including grants, contracts, and other transactions) submitted **on or after January 18, 2017** that request support (*in whole or in part*) for the conduct of any clinical trial
- if the grantee submits a competing renewal application that includes a new clinical trial
- to an “applicable clinical trial”, as defined by FDAAA, for existing studies initiated prior to 2017

1 <https://www.federalregister.gov/documents/2016/09/21/2016-22379/nih-policy-on-the-dissemination-of-nih-funded-clinical-trial-information>

2 <https://grants.nih.gov/policy/clinical-trials/reporting/faq.htm#5053>

3 <https://www.federalregister.gov/documents/2016/09/21/2016-22379/nih-policy-on-the-dissemination-of-nih-funded-clinical-trial-information#p-61>

4 <https://www.gpo.gov/fdsys/pkg/FR-2016-09-21/pdf/2016-22379.pdf>

5 HHS Agencies (includes NIH): <https://www.hhs.gov/about/agencies/hhs-agencies-and-offices/index.html>

\* FDAAA, \*\* Final Rule / 42 CFR Part 11

Specific to a funding opportunity announcement (FOA) / Review the **Notice of Award** document, in **Section III (Terms and Conditions, R&D paragraph)**

# NIH POLICY

## Definition of a Clinical Trial <sup>1, 2</sup>

A research study in which one or more **human subjects** are **prospectively assigned** to one or more **interventions** (which may include placebo or other control) to evaluate the effects of those interventions on **health-related biomedical or behavioral outcomes**.

1 <https://www.federalregister.gov/d/2016-22379/p-70>

2 <https://grants.nih.gov/policy/clinical-trials/definition.htm>


Unpacking the definition (slides 5 & 6): [https://grants.nih.gov/sites/default/files/Clinical-Trials-Changes-full%20length\\_v5.pptx](https://grants.nih.gov/sites/default/files/Clinical-Trials-Changes-full%20length_v5.pptx)

Case Studies: <https://grants.nih.gov/policy/clinical-trials/case-studies.htm>

FAQs: [https://grants.nih.gov/grants/policy/faq\\_clinical\\_trial\\_definition.htm](https://grants.nih.gov/grants/policy/faq_clinical_trial_definition.htm)

March 2018 - possible update to definition for *basic behavioral research*:

- <http://www.sciencemag.org/news/2018/03/final-2018-budget-bill-eases-biomedical-researchers-policy-worries>



# NIH POLICY

## *Responsible Party* <sup>1, 2, 3</sup>

### **NIH-Funded Clinical Trial is subject only to the NIH Policy:**

- The recipient or investigator

### **NIH-Funded Clinical Trial is subject to the DHHS Final Rule:**

- The Sponsor, or
- The Principal Investigator, if designated by the sponsor, grantee, contractor, or awardee

**Registration at ClinicalTrials.gov:** within 21 days after enrollment of the first research participant <sup>4</sup>

**Results Submission at ClinicalTrials.gov:** within 12 months after primary completion date <sup>5</sup>

<sup>1</sup> <https://www.federalregister.gov/documents/2016/09/21/2016-22379/nih-policy-on-the-dissemination-of-nih-funded-clinical-trial-information#p-62>

<sup>2</sup> <https://grants.nih.gov/policy/clinical-trials/reporting/steps.htm#>

<sup>3</sup> <https://www.federalregister.gov/d/2016-22379/p-74>

<sup>4</sup> [https://clinicaltrials.gov/ct2/manage-recs/faq#fr\\_5](https://clinicaltrials.gov/ct2/manage-recs/faq#fr_5)

<sup>5</sup> [https://clinicaltrials.gov/ct2/manage-recs/faq#fr\\_7](https://clinicaltrials.gov/ct2/manage-recs/faq#fr_7)

**REQUIRED GCP TRAINING:** <https://grants.nih.gov/policy/clinical-trials/good-clinical-training.htm> <https://grants.nih.gov/grants/guide/notice-files/NOT-OD-16-148.html>

**NONCOMPLIANCE:** <https://www.federalregister.gov/documents/2016/09/21/2016-22379/nih-policy-on-the-dissemination-of-nih-funded-clinical-trial-information#p-82>

# DHHS FINAL RULE

## *Definition of an Applicable Clinical Trial*<sup>1, 2, 3</sup>

### **Applicable Device Clinical Trial**

1) Controlled trials with health outcomes of devices subject to FDA regulation, other than small feasibility studies, and 2) pediatric postmarket surveillance required by FDA

### **Applicable Drug Clinical Trial**

Controlled clinical investigations, other than phase 1 clinical investigations, of drugs or biological products subject to Food and Drug Administration (FDA) regulation

### **A note about Expanded Access**

Information on the availability of investigational drug products (including biological drug products) for expanded access will continue to be required to be submitted to the *Clinical Trials.gov* database.<sup>4</sup>

<sup>1</sup> <https://www.federalregister.gov/documents/2016/09/21/2016-22129/clinical-trials-registration-and-results-information-submission#p-1297>

<sup>2</sup> <https://clinicaltrials.gov/ct2/manage-recs/fdaaa#WhichTrialsMustBeRegistered>

<sup>3</sup> [https://grants.nih.gov/clinicaltrials\\_fdaaa/docs/Flow\\_chart-ACT\\_only.pdf](https://grants.nih.gov/clinicaltrials_fdaaa/docs/Flow_chart-ACT_only.pdf)

<sup>4</sup> <https://www.federalregister.gov/documents/2016/09/21/2016-22129/clinical-trials-registration-and-results-information-submission#p-335>

# DHHS FINAL RULE

## *Responsible Party*<sup>1, 2</sup>

- The Sponsor, or
- The Principal Investigator, if designated by the sponsor, grantee, contractor, or awardee

***Final Rule: effective January 18, 2017 / compliance date of April 18, 2017***

**Registration at ClinicalTrials.gov:** within 21 days after enrollment of the first research participant<sup>3, 4</sup>

**Results Submission at ClinicalTrials.gov:** within 12 months after primary completion date<sup>5, 6</sup>

1 <https://www.federalregister.gov/documents/2016/09/21/2016-22129/clinical-trials-registration-and-results-information-submission#p-1167>

2 <https://clinicaltrials.gov/ct2/manage-recs/fdaaa#WholsResponsibleForRegistering>

3 <https://www.federalregister.gov/documents/2016/09/21/2016-22129/clinical-trials-registration-and-results-information-submission#p-1319>

4 [https://clinicaltrials.gov/ct2/manage-recs/faq#fr\\_5](https://clinicaltrials.gov/ct2/manage-recs/faq#fr_5)

5 <https://www.federalregister.gov/documents/2016/09/21/2016-22129/clinical-trials-registration-and-results-information-submission#p-1440>

6 [https://clinicaltrials.gov/ct2/manage-recs/faq#fr\\_7](https://clinicaltrials.gov/ct2/manage-recs/faq#fr_7)



FAQs: <https://clinicaltrials.gov/ct2/manage-recs/faq>

Registration & Results submission - table (prior to 2007, and on/after effective date of final rule): <https://www.federalregister.gov/d/2016-22129/p-961>

NOTE: Being **unfunded** does **not** exclude applicable clinical trials (ACTs) from the requirement to register.

**NONCOMPLIANCE:** <https://www.federalregister.gov/documents/2016/09/21/2016-22129/clinical-trials-registration-and-results-information-submission#p-1682>

Noncompliance (page 6), [2016 NEJM article](#): The FDAAA and the NIH policy hold all parties responsible for clinical trials (not just the individual investigators) accountable. [DOI: 10.1056/NEJMs1611785]



### REGISTRATION

- [How to Register](#)
- [Tutorial \(page 13/slide 25\)](#)
- [Data Elements Defined](#)
- [Criteria for the review of your submission](#)

### EDITING / UPDATING

- [How to Edit / When to Update Your Record](#)

### RESULTS SUBMISSION

- [How to Submit Results](#)
- [Criteria for the review of your results](#)

	SCOPE	DEFINITION	RESPONSIBLE PARTY	REGISTRATION & RESULTS SUBMISSION
<p><b><u>NIH POLICY</u></b></p> <p>* Review the <i>Notice of Award</i> document, in <b>Section III (Terms and Conditions - R&amp;D paragraph)</b></p>	<p><b><u>Applies:</u></b></p> <ul style="list-style-type: none"> <li>to all applications for NIH funding (including grants, contracts, and other transactions) submitted <b>on or after January 18, 2017</b> that request support (<i>in whole or in part</i>) for the conduct of any clinical trial</li> <li>if the grantee submits a competing renewal application that includes a new clinical trial</li> <li>to an “applicable clinical trial”, as defined by FDAAA, for existing studies initiated prior to 2017</li> </ul> <p><b><u>Does not apply to:</u></b></p> <ul style="list-style-type: none"> <li><u>clinical trials in ongoing, non-competing awards</u></li> <li><u>a clinical trial that uses NIH-supported infrastructure but does not receive NIH funds to support its conduct</u></li> <li><u>NIH-funded clinical trials initiated before the effective date</u></li> </ul>	<p>A research study in which one or more <b>human subjects</b> are <b>prospectively assigned</b> to one or more <b>interventions</b> (which may include placebo or other control) to evaluate the effects of those <b>interventions on health-related biomedical or behavioral outcomes.</b></p>	<p><b><u>NIH-Funded Clinical Trial is subject only to the NIH Policy:</u></b></p> <ul style="list-style-type: none"> <li>The recipient or investigator</li> </ul> <p><b><u>NIH-Funded Clinical Trial is subject to the DHHS Final Rule:</u></b></p> <ul style="list-style-type: none"> <li>The Sponsor, or</li> <li>The Principal Investigator, if designated by the sponsor, grantee, contractor, or awardee</li> </ul> <p><b><u>REQUIRED GCP TRAINING</u></b></p> <p><b><u>NONCOMPLIANCE</u></b></p>	<p><b>Registration at <a href="https://clinicaltrials.gov">ClinicalTrials.gov</a>: within 21 days after enrollment of the first research participant</b></p> <p><b>Results Submission at <a href="https://clinicaltrials.gov">ClinicalTrials.gov</a>: within 12 months after primary completion date</b></p> <p><b>REGISTRATION</b></p> <ul style="list-style-type: none"> <li><a href="#">How to Register</a></li> <li><a href="#">Tutorial (page 13/slide 25)</a></li> <li><a href="#">Data Elements Defined</a></li> <li><a href="#">Criteria for the review of your submission</a></li> </ul> <p><b>EDITING / UPDATING</b></p> <ul style="list-style-type: none"> <li><a href="#">How to Edit / When to Update Your Record</a></li> </ul> <p><b>RESULTS SUBMISSION</b></p> <ul style="list-style-type: none"> <li><a href="#">How to Submit Results</a></li> <li><a href="#">Criteria for the review of your results</a></li> </ul> <p><b>VOLUNTARY SUBMISSION</b></p> <ul style="list-style-type: none"> <li><a href="#">FAQs</a></li> <li><a href="#">Flowchart and Checklist</a></li> </ul>
<p><b><u>DHHS FINAL RULE</u></b></p>	<p><b><i>Effective January 18, 2017 [Table: study initiated before 2007, after 2007, on/after Final Rule]</i></b></p> <p><b><u>Applicable Device Clinical Trial</u></b></p> <p>1) Controlled trials with health outcomes of devices subject to FDA regulation, other than small feasibility studies, and 2) pediatric postmarket surveillance required by FDA</p> <p><b><u>Applicable Drug Clinical Trial</u></b></p> <p>Controlled clinical investigations, other than phase 1 clinical investigations, of drugs or biological products subject to Food and Drug Administration (FDA) regulation</p> <p><b><u>A note about Expanded Access</u></b></p> <p>Information on the availability of investigational drug products (including biological drug products) for expanded access will continue to be required to be submitted to the <i>Clinical Trials.gov</i> database.</p>	<p>A research study in which one or more <b>human subjects</b> are <b>prospectively assigned</b> to one or more <b>interventions</b> (which may include placebo or other control) to evaluate the effects of those <b>interventions on health-related biomedical or behavioral outcomes.</b></p>	<ul style="list-style-type: none"> <li><a href="#">The Sponsor, or</a></li> <li><a href="#">The Principal Investigator, if designated by the sponsor, grantee, contractor, or awardee</a></li> </ul> <p><b>NOTE:</b> Being <b>unfunded</b> does <b>not</b> exclude applicable clinical trials (ACTs) from the requirement to register.</p> <p><b><u>NONCOMPLIANCE</u></b></p>	<p><b>EDITING / UPDATING</b></p> <ul style="list-style-type: none"> <li><a href="#">How to Edit / When to Update Your Record</a></li> </ul> <p><b>RESULTS SUBMISSION</b></p> <ul style="list-style-type: none"> <li><a href="#">How to Submit Results</a></li> <li><a href="#">Criteria for the review of your results</a></li> </ul> <p><b>VOLUNTARY SUBMISSION</b></p> <ul style="list-style-type: none"> <li><a href="#">FAQs</a></li> <li><a href="#">Flowchart and Checklist</a></li> </ul>

## UCI CONTACTS

**School of Medicine clinical trials:** Mark Bourbonnais ([Mbourbon@hs.uci.edu](mailto:Mbourbon@hs.uci.edu), 949-682-5440)

**Non-School of Medicine clinical trials:** Laverne Estanol ([Lestanol@uci.edu](mailto:Lestanol@uci.edu), 949-824-4704)

<https://www.research.uci.edu/compliance/human-research-protections/researchers/guidelines-for-registering-in-a-clinicaltrials.gov-registry.html>